Ablynx is looking for new partners to take its rheumatoid arthritis drug vobarilizumab into phase 3 development, after AbbVie turned down an option to license the drug. AbbVie has already paid the ...

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago. For Sanofi, the acquisition comes hot on ...

PG has served as an advisor or speaker or has received research support from 3NT, Ablynx, ALK, ArgenX, AstraZeneca, Bekaert Textiles, Genentech, GSK, Hall Allergy, Medtronic, Novartis, Regeneron ...

Ablynx, Chimerix, Karyopharm Therapeutics, Schering-Plough, ViiV Healthcare, the American Physician Institute, DiaSorin, the Association for the Advancement of Blood & Biotherapies, Ortho Clinical ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...

Finally, Ablynx has entered ALX-0081 into development for the treatment of coronary syndromes, the first dromedary-derived V HH molecule in clinical development. MAbs have historically been ...

Prior to BMS, she held positions of leadership at pharmaceutical companies Janssen and Merck, and served as CSO at biotech firms Jounce Therapeutics and Ablynx NV. She obtained a Doctor of ...

Attention is now moving to the remaining companies with proprietary antibody platforms, including Ablynx, of Ghent, Belgium; Regeneron, of Tarrytown, New York; and Seattle Genetics, of Seattle.

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable ...